NF-κB is an important regulator of cell survival, proliferation and differentiation.1 NF-κB signaling pathway has a critical role in carcinogenesis, thereby considered to be an important therapeutic target in cancer.2 Abnormal levels of constitutively activated NF-κB have been detected in various solid tumors,3 leukemias, and either in cells of lymphoma patients or lymphoma cell lines.4, 5 NF-κB could resist TRAIL-induced apoptosis in Burkitt's lymphoma (BL) cell lines infected by Epstein–Barr virus.6 All these results indicate that NF-κB is an interesting therapeutic target in lymphoma. This evidence concerns the gene TNFSF10 and Burkitt lymphoma.